Publication Date:
2020
abstract:
There is an urgent need to develop effective therapies for COVID-19. Here, we urge immunologists and clinicians to consider the potential of targeting the complement system in these patients.
Iris type:
1.1 Articolo in rivista
Keywords:
Betacoronavirus; Complement Inactivating Agents; Complement System Proteins; Coronavirus Infections; Drug Delivery Systems; Humans; Immunotherapy; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome, Adult; Complement Activation
List of contributors:
Risitano, A. M.; Mastellos, D. C.; Huber-Lang, M.; Yancopoulou, D.; Garlanda, C.; Ciceri, F.; Lambris, J. D.
Published in: